Catatonia in psychiatric illnesses

Dirk M. Dhossche, Lee Elizabeth Wachtel, Michal Goetz, Pascal Sienaert

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Increased interest in the demarcation of catatonia from other conditions such as schizophrenia and autism is shown in the new DSM-5 category Catatonia Not Elsewhere Classified (NEC) encompassing catatonia of uncertain origin or associated with developmental conditions. Catatonia NEC is an imminently relevant diagnosis in patients who meet criteria for catatonia but without clearly defined associated psychotic, affective, or medical disorders. Catatonia NEC should be considered when catatonic symptoms present in patients with autism spectrum disorders, developmental disorders such as Prader-Willi Syndrome and Down Syndrome, tic disorders and Tourette Syndrome, Kleine-Levin Syndrome, aseptic encephalitis such as Anti-N-methyl-D-aspartate Receptor encephalitis, Pervasive Refusal Syndrome, or complex posttraumatic conditions. Current experiences continue to support the use of benzodiazepines and ECT in catatonia as safe and effective treatments without the risk of worsening catatonia or precipitating Neuroleptic Malignant Syndrome as opposed to when antipsychotic medications are used as first-line or sole treatment Historical and contemporary clinical and experimental catatonia models are available for future research, focusing on motor circuitry dysfunction, abnormal neurotransmitters, epileptic discharges, genetics, neuroendocrine and immune abnormalities, fear reactions akin to the animal defense strategy of tonic immobility, and developmental risk factors. There have been advances in demarcating catatonia in a wide variety of patients as a treatable condition that requires prompt identification. Catatonia NEC in DSM-5 is likely to improve proper diagnosis and treatment of catatonia and to intensify research of this condition.

Original languageEnglish (US)
Title of host publicationThe Medical Basis of Psychiatry
Subtitle of host publicationFourth Edition
PublisherSpringer New York
Pages517-535
Number of pages19
ISBN (Electronic)9781493925285
ISBN (Print)9781493925278
DOIs
StatePublished - Jan 1 2016

Fingerprint

Catatonia
Psychiatry
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Kleine-Levin Syndrome
Tic Disorders
Neuroleptic Malignant Syndrome
Prader-Willi Syndrome
Tourette Syndrome
Pervasive Child Development Disorders
Encephalitis
Autistic Disorder
Down Syndrome
Benzodiazepines
Antipsychotic Agents
Fear
Neurotransmitter Agents
Schizophrenia

Keywords

  • Anti-N-methyl-D-aspartate Receptor encephalitis
  • Autism
  • Autism spectrum disorders
  • Autonomic symptoms
  • Benzodiazepines
  • Catatonia
  • Children and adolescents
  • Delirium
  • Developmental disorders
  • Electroconvulsive treatment (ECT)
  • Kleine-Levin Syndrome
  • Malignant
  • Mood disorder
  • Movement disorders
  • Neuroleptic Malignant Syndrome
  • Posttraumatic stress disorder
  • Psychomotor abnormalities
  • Psychosis
  • Schizophrenia
  • Self-injury
  • Tics
  • Tourette syndrome
  • Toxic Serotonergic Syndrome
  • Vagal nerve

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dhossche, D. M., Wachtel, L. E., Goetz, M., & Sienaert, P. (2016). Catatonia in psychiatric illnesses. In The Medical Basis of Psychiatry: Fourth Edition (pp. 517-535). Springer New York. DOI: 10.1007/978-1-4939-2528-5_27

Catatonia in psychiatric illnesses. / Dhossche, Dirk M.; Wachtel, Lee Elizabeth; Goetz, Michal; Sienaert, Pascal.

The Medical Basis of Psychiatry: Fourth Edition. Springer New York, 2016. p. 517-535.

Research output: Chapter in Book/Report/Conference proceedingChapter

Dhossche, DM, Wachtel, LE, Goetz, M & Sienaert, P 2016, Catatonia in psychiatric illnesses. in The Medical Basis of Psychiatry: Fourth Edition. Springer New York, pp. 517-535. DOI: 10.1007/978-1-4939-2528-5_27
Dhossche DM, Wachtel LE, Goetz M, Sienaert P. Catatonia in psychiatric illnesses. In The Medical Basis of Psychiatry: Fourth Edition. Springer New York. 2016. p. 517-535. Available from, DOI: 10.1007/978-1-4939-2528-5_27

Dhossche, Dirk M.; Wachtel, Lee Elizabeth; Goetz, Michal; Sienaert, Pascal / Catatonia in psychiatric illnesses.

The Medical Basis of Psychiatry: Fourth Edition. Springer New York, 2016. p. 517-535.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{9495a93c6c5e471e8fb2c8c58baf6cec,
title = "Catatonia in psychiatric illnesses",
abstract = "Increased interest in the demarcation of catatonia from other conditions such as schizophrenia and autism is shown in the new DSM-5 category Catatonia Not Elsewhere Classified (NEC) encompassing catatonia of uncertain origin or associated with developmental conditions. Catatonia NEC is an imminently relevant diagnosis in patients who meet criteria for catatonia but without clearly defined associated psychotic, affective, or medical disorders. Catatonia NEC should be considered when catatonic symptoms present in patients with autism spectrum disorders, developmental disorders such as Prader-Willi Syndrome and Down Syndrome, tic disorders and Tourette Syndrome, Kleine-Levin Syndrome, aseptic encephalitis such as Anti-N-methyl-D-aspartate Receptor encephalitis, Pervasive Refusal Syndrome, or complex posttraumatic conditions. Current experiences continue to support the use of benzodiazepines and ECT in catatonia as safe and effective treatments without the risk of worsening catatonia or precipitating Neuroleptic Malignant Syndrome as opposed to when antipsychotic medications are used as first-line or sole treatment Historical and contemporary clinical and experimental catatonia models are available for future research, focusing on motor circuitry dysfunction, abnormal neurotransmitters, epileptic discharges, genetics, neuroendocrine and immune abnormalities, fear reactions akin to the animal defense strategy of tonic immobility, and developmental risk factors. There have been advances in demarcating catatonia in a wide variety of patients as a treatable condition that requires prompt identification. Catatonia NEC in DSM-5 is likely to improve proper diagnosis and treatment of catatonia and to intensify research of this condition.",
keywords = "Anti-N-methyl-D-aspartate Receptor encephalitis, Autism, Autism spectrum disorders, Autonomic symptoms, Benzodiazepines, Catatonia, Children and adolescents, Delirium, Developmental disorders, Electroconvulsive treatment (ECT), Kleine-Levin Syndrome, Malignant, Mood disorder, Movement disorders, Neuroleptic Malignant Syndrome, Posttraumatic stress disorder, Psychomotor abnormalities, Psychosis, Schizophrenia, Self-injury, Tics, Tourette syndrome, Toxic Serotonergic Syndrome, Vagal nerve",
author = "Dhossche, {Dirk M.} and Wachtel, {Lee Elizabeth} and Michal Goetz and Pascal Sienaert",
year = "2016",
month = "1",
doi = "10.1007/978-1-4939-2528-5_27",
isbn = "9781493925278",
pages = "517--535",
booktitle = "The Medical Basis of Psychiatry",
publisher = "Springer New York",

}

TY - CHAP

T1 - Catatonia in psychiatric illnesses

AU - Dhossche,Dirk M.

AU - Wachtel,Lee Elizabeth

AU - Goetz,Michal

AU - Sienaert,Pascal

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Increased interest in the demarcation of catatonia from other conditions such as schizophrenia and autism is shown in the new DSM-5 category Catatonia Not Elsewhere Classified (NEC) encompassing catatonia of uncertain origin or associated with developmental conditions. Catatonia NEC is an imminently relevant diagnosis in patients who meet criteria for catatonia but without clearly defined associated psychotic, affective, or medical disorders. Catatonia NEC should be considered when catatonic symptoms present in patients with autism spectrum disorders, developmental disorders such as Prader-Willi Syndrome and Down Syndrome, tic disorders and Tourette Syndrome, Kleine-Levin Syndrome, aseptic encephalitis such as Anti-N-methyl-D-aspartate Receptor encephalitis, Pervasive Refusal Syndrome, or complex posttraumatic conditions. Current experiences continue to support the use of benzodiazepines and ECT in catatonia as safe and effective treatments without the risk of worsening catatonia or precipitating Neuroleptic Malignant Syndrome as opposed to when antipsychotic medications are used as first-line or sole treatment Historical and contemporary clinical and experimental catatonia models are available for future research, focusing on motor circuitry dysfunction, abnormal neurotransmitters, epileptic discharges, genetics, neuroendocrine and immune abnormalities, fear reactions akin to the animal defense strategy of tonic immobility, and developmental risk factors. There have been advances in demarcating catatonia in a wide variety of patients as a treatable condition that requires prompt identification. Catatonia NEC in DSM-5 is likely to improve proper diagnosis and treatment of catatonia and to intensify research of this condition.

AB - Increased interest in the demarcation of catatonia from other conditions such as schizophrenia and autism is shown in the new DSM-5 category Catatonia Not Elsewhere Classified (NEC) encompassing catatonia of uncertain origin or associated with developmental conditions. Catatonia NEC is an imminently relevant diagnosis in patients who meet criteria for catatonia but without clearly defined associated psychotic, affective, or medical disorders. Catatonia NEC should be considered when catatonic symptoms present in patients with autism spectrum disorders, developmental disorders such as Prader-Willi Syndrome and Down Syndrome, tic disorders and Tourette Syndrome, Kleine-Levin Syndrome, aseptic encephalitis such as Anti-N-methyl-D-aspartate Receptor encephalitis, Pervasive Refusal Syndrome, or complex posttraumatic conditions. Current experiences continue to support the use of benzodiazepines and ECT in catatonia as safe and effective treatments without the risk of worsening catatonia or precipitating Neuroleptic Malignant Syndrome as opposed to when antipsychotic medications are used as first-line or sole treatment Historical and contemporary clinical and experimental catatonia models are available for future research, focusing on motor circuitry dysfunction, abnormal neurotransmitters, epileptic discharges, genetics, neuroendocrine and immune abnormalities, fear reactions akin to the animal defense strategy of tonic immobility, and developmental risk factors. There have been advances in demarcating catatonia in a wide variety of patients as a treatable condition that requires prompt identification. Catatonia NEC in DSM-5 is likely to improve proper diagnosis and treatment of catatonia and to intensify research of this condition.

KW - Anti-N-methyl-D-aspartate Receptor encephalitis

KW - Autism

KW - Autism spectrum disorders

KW - Autonomic symptoms

KW - Benzodiazepines

KW - Catatonia

KW - Children and adolescents

KW - Delirium

KW - Developmental disorders

KW - Electroconvulsive treatment (ECT)

KW - Kleine-Levin Syndrome

KW - Malignant

KW - Mood disorder

KW - Movement disorders

KW - Neuroleptic Malignant Syndrome

KW - Posttraumatic stress disorder

KW - Psychomotor abnormalities

KW - Psychosis

KW - Schizophrenia

KW - Self-injury

KW - Tics

KW - Tourette syndrome

KW - Toxic Serotonergic Syndrome

KW - Vagal nerve

UR - http://www.scopus.com/inward/record.url?scp=85026485227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026485227&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-2528-5_27

DO - 10.1007/978-1-4939-2528-5_27

M3 - Chapter

SN - 9781493925278

SP - 517

EP - 535

BT - The Medical Basis of Psychiatry

PB - Springer New York

ER -